Compare FRBA & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRBA | ENTA |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | 336 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.6M | 382.7M |
| IPO Year | N/A | 2012 |
| Metric | FRBA | ENTA |
|---|---|---|
| Price | $15.97 | $11.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $17.50 | ★ $20.40 |
| AVG Volume (30 Days) | 71.2K | ★ 204.4K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $14.68 | $7.76 |
| Revenue Next Year | $6.08 | N/A |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $14.41 | $6.44 |
| 52 Week High | $18.11 | $17.15 |
| Indicator | FRBA | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 28.16 |
| Support Level | $14.71 | $10.21 |
| Resistance Level | $16.07 | $11.74 |
| Average True Range (ATR) | 0.44 | 0.75 |
| MACD | 0.09 | -0.28 |
| Stochastic Oscillator | 75.74 | 4.51 |
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.